[{"NetIncomeLoss_1_Q2_USD":26302000.0,"SellingAndMarketingExpense_1_Q2_USD":6540000.0,"SellingAndMarketingExpense_2_Q2_USD":13561000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":27492000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":58861000.0,"AssetsCurrent_0_Q2_USD":188294000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":1108000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":79000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":169000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":3380000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-16955000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1760000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":5664000.0,"LiabilitiesNoncurrent_0_Q2_USD":79386000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":7975000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":12925000.0,"Depreciation_2_Q2_USD":3072000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":24863000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":166000.0,"Land_0_Q2_USD":991000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_2_Q2_USD":154000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":806000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":404000.0,"OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPortionAttributableToParent_1_Q2_USD":439000.0,"OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPortionAttributableToParent_2_Q2_USD":460000.0,"AccruedIncomeTaxesNoncurrent_0_Q2_USD":374000.0,"DeferredIncomeTaxAssetsNet_0_Q2_USD":8017000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":1482000.0,"LegalFees_1_Q2_USD":1030000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":6297000.0,"ShareBasedCompensation_2_Q2_USD":2291000.0,"Assets_0_Q2_USD":439169000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":22987000.0,"CommonStockSharesIssued_0_Q2_shares":43329294.0,"RoyaltyIncomeNonoperating_1_Q2_USD":2845000.0,"RoyaltyIncomeNonoperating_2_Q2_USD":3705000.0,"LegalFees_2_Q2_USD":2257000.0,"IncreaseDecreaseInOtherOperatingCapitalNet_2_Q2_USD":-36000.0,"OperatingLeaseLiability_0_Q2_USD":6447000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":145338000.0,"Revenues_2_Q2_USD":178181000.0,"Revenues_1_Q2_USD":85264000.0,"CommonStockValue_0_Q2_USD":null,"IncomeTaxExpenseBenefit_1_Q2_USD":6750000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":14219000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-1574000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-883000.0,"GoodwillPeriodIncreaseDecrease_2_Q2_USD":1110000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":44122000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":1296000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q2_USD":8000000.0,"EarningsPerShareBasic_1_Q2_USD":0.61,"EarningsPerShareBasic_2_Q2_USD":1.23,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":48391000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":6851000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":6065000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":43960000.0,"RepaymentsOfLinesOfCredit_2_Q2_USD":18824000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":77000.0,"OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_2_Q2_USD":66000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":4555000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":63374000.0,"OtherAssetsNoncurrent_0_Q2_USD":208909000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":2142000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":4363000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":26663000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":56701000.0,"IncreaseDecreaseInInventories_2_Q2_USD":12185000.0,"CommonStockNoParValue_0_Q2_USD":0.0,"OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent_1_Q2_USD":282000.0,"OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent_2_Q2_USD":240000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q2_USD":-2989000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_Q2_USD":-1942000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-15972000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.2,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.21,"OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_1_Q2_USD":80000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1_Q2_USD":77000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":11716000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1440000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":178181000.0,"InterestExpense_1_Q2_USD":472000.0,"InterestExpense_2_Q2_USD":1006000.0,"NonoperatingIncomeExpense_1_Q2_USD":-1149000.0,"NonoperatingIncomeExpense_2_Q2_USD":-1565000.0,"AccountsPayableCurrent_0_Q2_USD":16714000.0,"LiabilitiesCurrent_0_Q2_USD":50310000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":2016000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7491000.0,"BusinessCombinationContingentConsiderationLiabilityCurrent_0_Q2_USD":11296000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":43171000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":18706000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":41491000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1050000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":2291000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":33052000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":67300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":43244000.0,"Goodwill_0_Q2_USD":115296000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":2852000.0,"AccruedIncomeTaxesCurrent_0_Q2_USD":1502000.0,"NetIncomeLoss_2_Q2_USD":53081000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":41966000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":7671000.0,"ReceivablesNetCurrent_0_Q2_USD":44895000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":3389000.0,"OperatingLeasePayments_2_Q2_USD":1072000.0,"LongTermDebtNoncurrent_0_Q2_USD":50000000.0,"OtherAssetsMiscellaneousNoncurrent_0_Q2_USD":465000.0,"PreferredStockNoParValue_0_Q2_USD":0.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_1_Q2_shares":878000.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_Q2_shares":789000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.034,"GrossProfit_1_Q2_USD":57772000.0,"GrossProfit_2_Q2_USD":119320000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":78834000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":63374000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":361000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":3620000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":76303000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":118269000.0,"DerivativeLiabilitiesNoncurrent_0_Q2_USD":254000.0,"PreferredStockSharesAuthorized_0_Q2_shares":1000000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":12634000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":439169000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":-777000.0,"PreferredStockValue_0_Q2_USD":null,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1892000.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":127225000.0,"InvestmentIncomeInterest_2_Q2_USD":15000.0,"InventoryNet_0_Q2_USD":72534000.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_2_Q2_USD":-2698000.0,"OperatingIncomeLoss_1_Q2_USD":34201000.0,"OperatingIncomeLoss_2_Q2_USD":68865000.0,"BuildingsAndImprovementsGross_0_Q2_USD":32326000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":85264000.0,"InvestmentIncomeInterest_1_Q2_USD":6000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":4210000.0,"OperatingExpenses_2_Q2_USD":50455000.0,"OperatingExpenses_1_Q2_USD":23571000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q2_USD":7975000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q2_USD":7950000.0,"EarningsPerShareDiluted_1_Q2_USD":0.6,"EarningsPerShareDiluted_2_Q2_USD":1.21,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":5267000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":9860000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":162375000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0_Q2_USD":7300000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":505000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_1_Q2_USD":79000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2_Q2_USD":3380000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":11955000.0,"StockholdersEquity_0_Q2_USD":309473000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":177000.0,"ProfitLoss_2_Q2_USD":53081000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q2_USD":612000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":692000.0,"CommonStockSharesAuthorized_0_Q2_shares":71000000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":1108000.0,"Ticker":"VIVO","CIK":"794172","name":"MERIDIAN BIOSCIENCE INC","OfficialName":"Meridian Bioscience Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1192599275.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210507"}]